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The traditional approach of clinical genetic practice, known as the phenotype‐first approach, usually starts with a thorough review of electronic medical records of the patient and a complete evaluation of patient\'s clinical presentation, as well as a survey of family history. Often more than one experienced clinical geneticists will order a variety of additional laboratory or imaging tests to obtain relevant information in order to reach a reasonable clinical diagnosis. Finally, molecular testing often helps to confirm the clinical diagnosis. This practice requires the availability of electronic medical records, well trained clinical geneticists who are able to perform relevant clinical evaluation, order appropriate tests and understand the molecular reports. These critical components of clinical genetics are mostly lacking in China today,[1](#ped412036-bib-0001){ref-type="ref"} as a consequence, most of patients with genetic condition do not receive a proper evaluation by clinical geneticists, only a small percent of patients received a clinical diagnosis and the majority remains undiagnosed for life.

The advent of genome‐wide tests for clinically relevant alterations, especially chromosomal microarray and exome tests, offered a new approach, which is genotype‐first approach where a definitive diagnosis can be reached mainly based on molecular evidence. While electronic medical records, well trained clinical geneticists and genetic counselors are very important and desirable to have, we are appreciating more the value of the genotype‐first approach that are currently helping the genetic diagnostic services of the tens of thousands of patients with undiagnosed genetic conditions.

The value of such a practice is exemplified in the paper authored by Hao et al[2](#ped412036-bib-0002){ref-type="ref"} in this issue of Pediatric Investigation. Hao et al performed an exome analysis and successfully identified the causal variants for Antley‐Bixler syndrome, an exceptionally rare genetic disorder with a feature of craniosynostosis in a Chinese child patient. While craniosynostosis is not a feature that could be easily missed, yet this is a feature known to be associated with a large number of clinically heterogeneous conditions with equally heterogeneous genetic basis. While a clinical diagnosis of this patient with this rare condition is possible by experienced clinical geneticist, the arrival of a definitive diagnosis may not be as quickly as it was demonstrated in this paper by an exome test. The fact that this patient had gone through different clinics (from Endocrinology to Otolaryngology to Orthopedics) before coming to Genetics demonstrated the current status of our ability for clinical evaluation and diagnosis for rare genetic disorders in China where genotype‐first approach will continue to play an equalizing role for genetic diagnostics.

We all learn from practices, our clinicians will be able to arrive the right clinical diagnosis the next time when we encounter similar patients, thus the value of exome testing for this patient is more than getting the right diagnosis for this patient.
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